StreetInsider.com News Articles

Form 4 Camp4 Therapeutics Corp For: Jun 10 Filed by: Nashat Amir

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26640998.html

Form 4 Camp4 Therapeutics Corp For: Jun 10 Filed by: Stewart Murray

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26641002.html

Form 4 Camp4 Therapeutics Corp For: Jun 10 Filed by: Holtzman Steven H

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26641010.html

Form 4 Camp4 Therapeutics Corp For: Jun 10 Filed by: Young Richard A

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26641018.html

Form 4 Camp4 Therapeutics Corp For: Jun 10 Filed by: WILLIAMS DOUGLAS E

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26641021.html

Form 4 Camp4 Therapeutics Corp For: Jun 10 Filed by: Schwab Andrew J.

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26641024.html

Chardan Starts CAMP4 Therapeutics Corp (CAMP) at Buy

Wed, 10 Jun 2026 04:54:46 -0400

Chardan analyst Keay Nakae initiates coverage on CAMP4 Therapeutics Corp (NASDAQ: CAMP) with a Buy rating and a price target of $6.50.

The analyst comments: “We initiate coverage on CAMP4 Therapeutics with a Buy rating and a 12-month price target of $6.50 based on the potential of its novel regRNA-targeting strategy for modulation of gene expression.

• Camp4 is a clinical-stage biotech company focused on developing antisense oligonucleotides (ASOs) designed to bind to targeted non-coding RNA. Specifically, regulatory RNA (regRNAs), which act locally on transcription factors, in order to amplify gene expression. Utilizing its RAP Platform, the company has essentially mapped out

Chardan Starts CAMP4 Therapeutics Corp (CAMP) at Buy

Wed, 10 Jun 2026 04:54:46 -0400

Chardan analyst Keay Nakae initiates coverage on CAMP4 Therapeutics Corp (NASDAQ: CAMP) with a Buy rating and a price target of $6.50.

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 21 May 2026 16:05:00 -0400

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 21 May 2026 16:05:00 -0400

CAMP4 Therapeutics reports seizure improvements in preclinical study

Thu, 14 May 2026 07:00:47 -0400

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) announced preclinical data showing its experimental drug CMP-002 improved seizure threshold and severity in a mouse model of SYNGAP1-related disorder.

The Cambridge, Massachusetts-based company presented the findings at the TIDES Oligonucleotide & Peptide Therapeutics conference on May 14. The study used mice with SYNGAP1 haploinsufficiency, a genetic condition that reduces protein levels by approximately 50%.

Researchers induced seizures in the mice using pentylenetetrazol, a chemical that blocks GABA receptors and increases brain excitability. Mice with SYNGAP1 haploinsufficiency experienced more severe seizures compared to normal mice. However, those treated with a single dose of CMP-002 showed statistically significant

CAMP4 Therapeutics reports seizure improvements in preclinical study

Thu, 14 May 2026 07:00:47 -0400

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) announced preclinical data showing its experimental drug CMP-002 improved seizure threshold and severity in a mouse model of SYNGAP1-related disorder.

CAMP4 Therapeutics reports seizure improvements in preclinical study

Thu, 14 May 2026 07:00:47 -0400

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) announced preclinical data showing its experimental drug CMP-002 improved seizure threshold and severity in a mouse model of SYNGAP1-related disorder.

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

Thu, 14 May 2026 07:00:00 -0400